Welcome to our dedicated page for CARLSMED news (Ticker: CARL), a resource for investors and traders seeking the latest updates and insights on CARLSMED stock.
Carlsmed, Inc. (Nasdaq: CARL) is a medical technology company that reports on the commercial progress of its AI-enabled personalized spine surgery platform, aprevo. News about Carlsmed often centers on its revenue growth as a commercial-stage company, updates on surgeon adoption of the aprevo platform, and financial guidance shared in quarterly results and preliminary annual revenue announcements.
Investors following CARL news can expect regular earnings releases that discuss revenue, gross profit, operating expenses, net loss, cash and cash equivalents, and non-GAAP measures such as Adjusted EBITDA. These releases are typically accompanied by conference call and webcast details, and they are referenced in the company’s Form 8-K filings with the SEC. Carlsmed also issues news about amendments to its loan and security agreement and related warrant arrangements, which provide insight into its access to debt financing and capital structure.
Beyond financial updates, Carlsmed publishes news on clinical and product milestones for the aprevo Technology Platform. This includes announcements of clinical study publications in journals such as Global Spine Journal, data presented at meetings like the Scoliosis Research Society Annual Meeting, and the U.S. commercial launch of its aprevo Technology Platform for cervical fusion surgeries. The company’s releases highlight findings on revision rates, mechanical complications, and alignment outcomes when using personalized, patient-specific interbody implants and AI-enabled preoperative planning.
Carlsmed also announces participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and the Piper Sandler Healthcare Conference, as well as index-related developments like its addition to the Russell 2000 Index. These items provide context on how the market and the medical community engage with the company. For ongoing coverage of CARL, this news page aggregates Carlsmed’s financial disclosures, clinical updates, reimbursement developments, and corporate events in one place.
Carlsmed (Nasdaq: CARL) reported strong revenue growth with Q4 2025 revenue $15.2M (+61% YoY) and full-year 2025 revenue $50.5M (+86% YoY). Gross margin expanded to 75.3% for 2025 and cash resources were $109.9M at year-end. Management provided 2026 revenue guidance of $70–$75M.
Company highlighted published 2-year aprevo lumbar outcomes showing a 74% reduction in revision rates and multiple product and first-in-human procedural milestones in February 2026.
Carlsmed (Nasdaq: CARL) said CEO and Chairman Mike Cordonnier will present at the 2026 Canaccord Genuity Musculoskeletal Conference on March 2, 2026 at 11:30 AM CST in New Orleans. A live webcast is available to registered participants and a replay will be posted afterward.
Carlsmed (Nasdaq: CARL) announced the first personalized cervical plating procedure using the corra™ Cervical Plating System on Feb. 18, 2026.
The procedure, performed by Dr. Aaron Clark at UCSF, begins a clinical evaluation ahead of a planned commercial launch of corra™ later in 2026 and highlights integration with aprevo® planning and interbody devices.
Carlsmed (Nasdaq: CARL) will report fourth quarter and full year 2025 financial results after market close on Wednesday, February 25, 2026. Management will host a conference call and concurrent webcast at 1:30 PM Pacific Time, with a replay archived on the company's website.
Carlsmed (Nasdaq: CARL) announced the first posterior lumbar spine surgery using its aprevo® Lumbar Bi-lateral Posterior System, performed Feb. 10, 2026 at University of Colorado Hospital.
The company says the procedure demonstrates aprevo® integration across lumbar fusion approaches and expects a full commercial launch later in 2026.
Carlsmed (Nasdaq: CARL) reported preliminary unaudited revenue of approximately $15.2 million for the fourth quarter of 2025, about +61% versus Q4 2024, and preliminary full year 2025 revenue of approximately $50.5 million, about +86% versus 2024. The company said it added 101 new surgeon users in 2025, a 61% increase in its surgeon user base, and launched aprevo cervical with early positive surgeon feedback. Results are preliminary, unaudited and subject to revision until the Company files its 2025 Annual Report on Form 10-K.
Carlsmed (Nasdaq: CARL) announced publication of a retrospective cohort study in Global Spine Journal showing that 3D preoperative planning plus patient-specific aprevo® interbody implants reduced 2-year mechanical-complication revision rates to 4.3% (n=115) versus 16.6% (n=997) with conventional stock implants (p<0.001), a 74% relative reduction. The comparator cohort came from the International Spine Study Group dataset of senior spine surgeons. Authors note improved restoration of distal lumbar lordosis and potential reductions in proximal junctional kyphosis, reoperations, and economic burden. The peer-reviewed article is available online in Global Spine Journal.
Carlsmed (Nasdaq: CARL) announced that Mike Cordonnier, Chairman and CEO, will present at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14, 2026 from 4:30–5:10 PM PT in San Francisco.
Carlsmed management also said it will host one-on-one investor meetings during the conference.
Carlsmed (Nasdaq: CARL) announced the U.S. commercial launch of its aprevo® Technology Platform for cervical fusion on December 3, 2025, and will present early clinical experience at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting, December 3–6, 2025.
The aprevo® Cervical Interbody System pairs AI-driven preoperative planning with 3D-printed, patient-specific implants. Carlsmed reported its first 50+ cervical cases, noting efficient workflow integration, precise implant fit with maximized endplate coverage, and an ability to achieve planned sagittal and coronal alignment versus stock implants.
Carlsmed referenced prior aprevo® lumbar results showing lower complication rates and fewer revision surgeries, cited 370,000 U.S. cervical fusions performed this year as market context, and will hold a CSRS lunch workshop on Dec 4, 2025 at 12:30 PM EST.
Carlsmed (Nasdaq: CARL) announced that Chairman and CEO Mike Cordonnier will present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 from 9:00–9:25 AM ET in New York.
Management will host one-on-one investor meetings, a live webcast will be available to registered participants, and a replay will be posted at https://investors.carlsmed.com/.